PledPharma AB | Innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments does not exist

PledPharma has an innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments do not exist.

Extraordinary General Meeting

Postal voting

Pipeline

Analyst presentation; acquisition of RTT

Go to the link

Press Releases

Regulatory

October 20, 2020

Nomination Committee appointed for the 2021 Annual General Meeting in PledPharma

October 14, 2020

Design of pivotal Phase IIb/III study for Aladote® finalized after completed interactions with FDA, EMA and MHRA

Regulatory

October 5, 2020

Notice of Extraordinary general meeting in PledPharma AB

Latest Report

August 20, 2020

Latest interim report

March 30, 2020

Annual report 2019 (in Swedish)

Latest presentation

October 19, 2020

Swedish Shareholders' Association, Shareholders' day

Calendar and upcoming reports

November 11, 2020

Interim report third quarter 2020

October 28, 2020

Extrodinary general meeting

February 17, 2021

Year end report

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com